Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program

While Tacere is weighing the possible expansion of its pipeline, having met this milestone in its flagship drug-development program, the company's management has set its sights on exiting the field through the sale of the company to a bigger player.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories